Related Experiment Video
Updated: Sep 14, 2025

07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
15.1K
Design of high-specificity binders for peptide-MHC-I complexes
Bingxu Liu1,2, Nathan F Greenwood1,2, Julia E Bonzanini1,2,3
1Department of Biochemistry, University of Washington, Seattle, WA, USA.
Summary
Scientists designed novel proteins targeting diseased cells by recognizing specific peptide-MHC-I (pMHCI) complexes. These engineered binders, when used in chimeric antigen receptors, successfully activated T cells, showing potential for new cancer therapies.
Area of Science:
- Immunology
- Protein Engineering
- Computational Biology
Background:
- Class I major histocompatibility complex (MHC-I) molecules present intracellular peptides for immune surveillance.
- Targeting disease-specific peptide-MHC-I (pMHCI) complexes offers therapeutic potential.
- Achieving specificity requires recognizing disease-associated peptides while avoiding ubiquitous MHC interactions.
Purpose of the Study:
- To design novel pMHCI-binding proteins with high specificity for diseased cells.
- To utilize computational methods for protein design against specific pMHCI targets.
- To validate the therapeutic potential of designed binders in T cell activation.
Main Methods:
- Employed RFdiffusion, a protein design algorithm, to generate pMHCI binders.
- Initiated design processes from experimental or predicted pMHCI structures.
- Incorporated designed binders into chimeric antigen receptors (CARs) for functional testing.
Main Results:
- Successfully identified specific binders for 11 distinct target pMHCI complexes.
- Designs demonstrated extensive contacts with the peptide portion of pMHCI.
- CARs incorporating eight of the designed binders mediated peptide-specific T cell activation.
Conclusions:
- The developed protein design approach enables targeted recognition of disease-associated pMHCI.
- Engineered pMHCI binders show promise for developing novel immunotherapies.
- This strategy has broad applicability for both protein- and cell-based pMHCI targeting.

